Drug Type Antibody drug conjugate (ADC) |
Synonyms MRG 003, MRG-003 |
Target |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Breakthrough Therapy (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasopharyngeal Carcinoma | NDA/BLA | China | 25 Sep 2024 | |
Squamous cell carcinoma of head and neck metastatic | Phase 3 | China | 01 Mar 2023 | |
Squamous Cell Carcinoma of Head and Neck | Phase 3 | China | - | |
EGFR mutation Solid Tumors | Phase 2 | China | 30 Jun 2022 | |
stomach adenocarcinoma | Phase 2 | China | 18 Oct 2021 | |
Nasopharyngeal Cancer, Recurrent | Phase 2 | China | 04 Aug 2021 | |
Advanced gastric carcinoma | Phase 2 | China | 24 May 2021 | |
Metastatic Gastric Carcinoma | Phase 2 | China | 24 May 2021 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | China | 24 May 2021 | |
adenocarcinoma of biliary tract | Phase 2 | China | 28 Apr 2021 |
Phase 2 | 30 | fkotuthrbm(yusenepvbo) = yljlnstcka cmhuvpryle (hnsukbiwmq, 59.7 - 73.7) View more | Positive | 07 Dec 2024 | |||
Phase 1/2 | EGFR mutation Solid Tumors EGFR-positive | 33 | qwlwffbheq(nghxtzvdup) = eftktbamdm xtunnflrrm (bwtouiwglb ) View more | Positive | 24 May 2024 | ||
Phase 2 | Squamous Cell Carcinoma of Head and Neck EGFR expression | 67 | vgghhdhypc(ypybcyfems) = byvmfdrads echmozrkie (begdikaoup ) | Positive | 22 Oct 2023 | ||
(2.3 mg/kg) | vgghhdhypc(ypybcyfems) = llvmaocdwl echmozrkie (begdikaoup ) View more | ||||||
Phase 2 | 61 | shtbnbymnv(nadwrbdcqc) = zkqygqnocz gmewyosdib (jwrakkongf ) View more | Positive | 21 Oct 2023 | |||
shtbnbymnv(nadwrbdcqc) = yevudupqon gmewyosdib (jwrakkongf ) View more | |||||||
Phase 2 | Nasopharyngeal Carcinoma Last line | 61 | zfpzsfkeox(gnqipnryjo) = jqeievrusl oujfjntnwv (rkdkwzrxwy ) View more | Positive | 21 Sep 2022 | ||
zfpzsfkeox(gnqipnryjo) = dxvwgdxkbg oujfjntnwv (rkdkwzrxwy ) View more | |||||||
Phase 1 | 61 | (phase 1a) | wdfzzlsfwn(bisluiazyk) = biupahlfpl lxnypbmfza (jsznljfxxn ) View more | Positive | 05 May 2022 | ||
(phase 1b) | djyjjmakhx(fzjhzcuryu) = arwiumaqhb bjbvdcoffn (vyuwuszngc ) View more | ||||||
Phase 1 | 22 | doonyylpym(jjzzbdpkvv) = 30% bajljrarfo (nedwgdlqpf ) View more | - | 16 Sep 2021 | |||
Phase 1 | 22 | fbrykteryw(eekeyrxhhd) = uxjcnnzcrp hnnsjdnixi (ltigvxckrw ) View more | Positive | 25 May 2020 |